BlackRock’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-357,192
| Closed | -$50K | – | 5392 |
|
|
2024
Q1 | $50K | Sell |
357,192
-430
| -0.1% | -$85 | ﹤0.01% | 4869 |
|
|
2023
Q4 | $52K | Sell |
357,622
-13,021
| -4% | -$2.02K | ﹤0.01% | 4961 |
|
|
2023
Q3 | $64.9K | Sell |
370,643
-4,146
| -1% | -$5.15K | ﹤0.01% | 4954 |
|
|
2023
Q2 | $1.17M | Buy |
374,789
+55,269
| +17% | +$164K | ﹤0.01% | 4249 |
|
|
2023
Q1 | $818K | Buy |
319,520
+22,197
| +7% | +$45.8K | ﹤0.01% | 4388 |
|
|
2022
Q4 | $443K | Sell |
297,323
-14,907
| -5% | -$24.2K | ﹤0.01% | 4644 |
|
|
2022
Q3 | $543K | Sell |
312,230
-2,429
| -0.8% | -$3.43K | ﹤0.01% | 4703 |
|
|
2022
Q2 | $410K | Sell |
314,659
-6,633
| -2% | -$11.4K | ﹤0.01% | 4835 |
|
|
2022
Q1 | $765K | Buy |
321,292
+149,253
| +87% | +$389K | ﹤0.01% | 4757 |
|
|
2021
Q4 | $790K | Sell |
172,039
-13,871
| -7% | -$45.9K | ﹤0.01% | 4738 |
|
|
2021
Q3 | $1.5M | Buy |
185,910
+769
| +0.4% | +$6.59K | ﹤0.01% | 4434 |
|
|
2021
Q2 | $1.82M | Sell |
185,141
-406,586
| -69% | -$3.3M | ﹤0.01% | 4313 |
|
|
2021
Q1 | $5.22M | Buy |
591,727
+54,762
| +10% | +$601K | ﹤0.01% | 3926 |
|
|
2020
Q4 | $5.49M | Buy |
536,965
+114,325
| +27% | +$1.25M | ﹤0.01% | 3665 |
|
|
2020
Q3 | $3.82M | Buy |
422,640
+25,463
| +6% | +$202K | ﹤0.01% | 3686 |
|
|
2020
Q2 | $2.84M | Buy |
397,177
+325,620
| +455% | +$3.46M | ﹤0.01% | 3721 |
|
|
2020
Q1 | $680K | Buy |
71,557
+3,923
| +6% | +$50.6K | ﹤0.01% | 3985 |
|
|
2019
Q4 | $890K | Buy |
+67,634
| New | +$825K | ﹤0.01% | 4031 |
|
Other funds holding GRTX
BlackRock's GRTX Position: Q2 2024 in Review
BlackRock sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 357,192 shares — an estimated $50K sold.
BlackRock first reported a position in GRTX in Q4 2019 and held it in 18 quarters. The position peaked at $5.49M in Q4 2020. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.
- BlackRock reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 357,192 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $50K.
- BlackRock first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 18 quarters.
- BlackRock's Galera Therapeutics, Inc. Common Stock position peaked at $5.49M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.